All In Biotech

Drug Trial Radar · NCT07303777

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics (PopPK) Profile of ABP-745 in Patients With Atherosclerosis

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Jan 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Atom Therapeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Dec 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.

Conditions

  • Atherosclerosis Cardiovascular Disease
  • ASCVD
  • ASCVD Management

Interventions

  • ABP-745 Dose ADrug

    ABP-745 Dose A - tablets (PO), low dose , QD

  • PlaceboDrug

    ABP-745 placebo - tablets (PO), non-active,QD

  • ABP-745 Dose BDrug

    ABP-745 Dose B - tablets (PO), Midum dose, QD

  • ABP-745 Dose CDrug

    ABP-745 Dose C - tablets (PO), High dose, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from the baseline in percent atheroma volume (PAV)Time frame: 52 weeks after treatment

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Cardiovascular Research Foundation of Southern California

    Beverly Hills, California · Not yet recruiting

  • Cardiovascular Institute of San Diego INC

    San Diego, California · Not yet recruiting

  • The Lundquist Institute

    Torrance, California · Not yet recruiting

  • Washington University School of Medicine, St.louis

    St Louis, Missouri · Not yet recruiting

  • Core Research Group Pty Ltd

    Brisbane, Australia · Not yet recruiting

  • UniSC Clinical Trials (Brisbane)

    Brisbane, Australia · Not yet recruiting

  • Cognivus

    Wahroonga, Australia · Not yet recruiting

  • NovaTrails

    Newcastle, New South Wales, Australia · Not yet recruiting

  • University of the Sunshine Coast Clinical Trials Unit - Morayfield

    Morayfield, Queensland, Australia · Not yet recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China · Not yet recruiting

  • Peking Union Medical College Hospital

    Beijing, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, China · Not yet recruiting

  • Xuanwu Hospital Capital Medical University

    Beijing, China · Not yet recruiting

  • Dalian Second Hospital

    Dalian, China · Not yet recruiting

  • Guangdong Province Hospital

    Guangzhou, China · Not yet recruiting

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • The First Affiliated Hospital of Zhejiang University school of medicine

    Hangzhou, China · Not yet recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, China · Not yet recruiting

  • Jinan Central Hospital

    Jinan, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Not yet recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, China · Not yet recruiting

  • Huashan Hospital Fudan University

    Shanghai, China · Not yet recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Not yet recruiting

  • Shanghai General Hospital

    Shanghai, China · Not yet recruiting

  • The Zhongshan Hospital Affiliated to Fudan University

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, China · Not yet recruiting

  • Tianjin General Hospital

    Tianjin, China · Not yet recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, China · Not yet recruiting

  • Wuxi People's Hospital

    Wuxi, China · Not yet recruiting

  • Shaanxi Provincial People's Hospital

    Xi'an, China · Not yet recruiting

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, China · Not yet recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China · Not yet recruiting

  • The Affiliated Hospital of Xuzhou Medical College

    Xuzhou, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.